Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis

Figure 2 Unadjusted and adjusted hazard ratios of fibrosis-4 index (A), aspartate aminotransferase to platelet ratio score (B), liver stiffness measurement (C), and hepatocellular carcinoma risk. ¹Cirrhosis and direct acting antiviral-treated cohort. ²Cirrhosis and interferon-treated cohort. ³Non-cirrhotic and direct acting antiviral-treated cohort. ⁴Non-cirrhotic and interferon-treated cohort. ⁵Sustained virologic response cohort. ⁶Non-sustained virologic response cohort. DAA: Direct-acting antiviral; FIB-4: Fibrosis-4 index; pegIFN/RBV: Pegylated interferon and ribavirin; SVR: Sustained virologic response.